Richard McCormick

Richard McCormick is the Founder and Principal of ImmunoInnova IP Consulting.

Innovator pharmaceutical and biotech companies have relied on Richard McCormick for over 25 years for legal representation in developing, assessing, strengthening, and enforcing (or defending against) a broad array of patent portfolios. As a Partner in the international law firm Mayer Brown LLP, he represented Bristol-Myers Squibb, Sanofi, Regeneron, GlaxoSmithKline, Gilead, and Alexion, among other large-cap companies in the pharma and biotech industry, in patent infringement litigations and licensing disputes, UPSTO post-grant proceedings, pre-litigation assessments, patent portfolio due diligence, freedom to operate analyses, and competitive landscaping.

Richard is presently the Founder and Principal of ImmunoInnova Intellectual Property Consulting, focusing on advice to the industry on large-molecule drugs, particularly antibodies and other biologics-related immunotherapies and interventions (CAR-T, gene therapy, and vaccines), and associated platform technologies, formulations, delivery systems, manufacturing processes, and methods of treatment. He is the co-author of the chapter Reference Product Sponsor Counseling and Strategies in Biosimilars Litigation and Client Counseling (ABA Book Publishing, 2024). The Legal Media Group Life Sciences guide has ranked him as a “Leading Life Sciences Lawyer” in Intellectual Property, and the Intellectual Asset Management Patent 1000 placed him in its bronze tier, calling him an “inimitable litigation strategist and regulatory expert.”

Before entering law school, Richard did graduate work towards a Ph.D. in biochemistry and was a research assistant in the Department of Molecular Biology at Princeton University and the Department of Pediatric Oncology at the Dana-Farber Cancer Institute.